Preimplantation Genetics Diagnosis (PGD) Market (By Test Type: Gender Selection, Chromosomal Abnormalities, Single Gene Disorders, HLA Typing, Aneuploidy, And Others; By Geography) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024
|出版商||Variant Market Research LLP||商品編碼||557047|
|出版日期||內容資訊||英文 119 Pages
|胚胎著床前遺傳基因診斷 (PGD)的全球市場:市場方案，市場規模，預測，趨勢，預測 Preimplantation Genetics Diagnosis (PGD) Market (By Test Type: Gender Selection, Chromosomal Abnormalities, Single Gene Disorders, HLA Typing, Aneuploidy, And Others; By Geography) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024|
|出版日期: 2017年09月12日||內容資訊: 英文 119 Pages||
本報告提供全球胚胎著床前遺傳基因診斷 (PGD) 市場相關調查，彙整市場趨勢與檢驗類別，地區別趨勢，及打入市場的主要企業簡介等資料。
Global Preimplantation Genetics Diagnosis (PGD) Market is estimated to reach $140 Million by 2024; growing at a CAGR of 6.2% from 2016 to 2024. Preimplantation genetic diagnosis is a procedure which involves genetic profiling of embryos, so as to reduce the possibility of passing on inherited disorders. It aids in detecting embryos with abnormalities and selects healthy embryo that can be used for implanting in the uterus. It decreases the rate of unprompted abortion and increased the probabilities of delivering genetically healthy baby. It majorly helps couples whose offspring are capable of getting affected by severe mendelian disorders, mitochondrial disorders or structural chromosome abnormalities. Presently, PGD is the only available technique which are used to avoid highly affected embryo before implantation.
The factors driving the global preimplantation genetics diagnosis (PGD) market includes decreasing fertility rate, technological advancements in the field of genetic analysis, rising demand for IVF treatments, increasing commonness of genetic disorders, and risk of affecting genetic disorders in embryos with increasing maternal age. Though, ethical and economic concerns and several government regulations would hinder the growth of the market. Furthermore, technological advancements and untapped markets would provide numerous growth opportunities in the forecast period.
The global preimplantation genetics diagnosis (PGD) is segmented on the basis of test type and geography. Test type is further bifurcated as X-linked diseases, HLA typing, chromosomal abnormalities, gender selection, single gene disorders, aneuploidy, and other test types.
Based on geography, global market is segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is further bifurcated in U.S., Canada, and Mexico whereas Europe consist of UK, Germany, France, and others. Asia-Pacific is segmented into India, China, Japan, and others, while RoW is bifurcated into South America, Middle East and Africa.
The key market players include Thermo Fisher Scientific, Inc., Cooper Surgical, Inc., Abbott Laboratories, Agilent Technologies, Inc., Natera, Inc., PerkinElmer, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., PerkinElmer, Inc., and Beijing Genomics Institute (BGI), among others.
Test Type Segments